Research Paper
Preferential involvement of CX chemokine receptor 4 and CX chemokine ligand 12 in T-Cell migration toward melanoma cells
Downloads and Tools
Volume 5, Issue 10 October 2006
Pages 1304 - 1312
http://dx.doi.org/10.4161/cbt.5.10.3153
Authors: Tianqian Zhang, Rajasekharan Somasundaram, Carol Berking, Laura Caputo, Patricia Van Belle, David E. Elder, Brian Czerniecki, Susan Hotz, Lynn Schuchter, Francis R. Spitz, Klara Berencsi, Pyapalli Rani, Francesco Marincola, Ruihua Qiu and Dorothee Herlyn
View affiliations Hide affiliations
- Tianqian Zhang
-
The Wistar Institute, Philadelphia, PA
- Rajasekharan Somasundaram
-
The Wistar Institute, Philadelphia, PA
- Carol Berking
-
The Wistar Institute, Philadelphia, PA
- Laura Caputo
-
The Wistar Institute, Philadelphia, PA
- Patricia Van Belle
-
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- David E. Elder
-
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- Brian Czerniecki
-
Hospital of University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- Susan Hotz
-
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- Lynn Schuchter
-
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- Francis R. Spitz
-
Hospital of University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- Klara Berencsi
-
The Wistar Institute, Philadelphia, PA
- Pyapalli Rani
-
The Wistar Institute, Philadelphia, PA
- Francesco Marincola
-
National Institutes of Health, Bethesda, MD
- Ruihua Qiu
-
The Wistar Institute, Philadelphia, PA
- Dorothee Herlyn
-
The Wistar Institute, Philadelphia, PA
Abstract:
Our previous analysis of the role of chemokines in T lymphocyte trafficking toward human tumor cells revealed the migration of a melanoma patient's cytotoxic T lymphocytes (CTL) toward autologous tumor cells, resulting in tumor cell apoptosis, in an organotypic melanoma culture. CTL migration was mediated by CX chemokine receptor (CXCR) 4 expressed by the CTL and CX chemokine ligand (CXCL) 12 secreted by the tumor cells, as evidenced by blockage of CTL migration by antibodies to CXCL12 or CXCR4, high concentrations of CXCL12 or small molecule CXCR4 antagonist. Here, we present the results of T cell migration in one additional melanoma patient and T cell and tumor cell analyses for CXCR4 and CXCL12 expression, respectively, in 12 additional melanoma patients, indicating the preferential role of CXCR4 and CXCL12 in CTL migration toward melanoma cells. These studies add to the increasing body of evidence suggesting that CXCL12 is a potent chemoattractant for T cells.
Preview: